Co-administration of aspirin and clopidogrel enhances the inhibition of platelet aggregation and thus reduces acute infarction. However, one should be wary of bleeding and hematologic abnormalities. Clopidogrel inhibits platelet aggregation by selectively inhibiting the binding of adenosine diphosphate to platelet receptors, and the drug is used for the prevention of atherosclerotic thrombotic events, which may cause adverse reactions such as rhinorrhea and gastrointestinal bleeding, and is contraindicated in those with active bleeding and severe liver injury. Aspirin, on the other hand, works by irreversibly inhibiting the synthesis of cyclooxygenase. The drug can also be used to prevent recurrence of stroke and myocardial infarction, but may cause gastrointestinal discomfort, bleeding gums, and other adverse reactions. It should not be used by those who have severe liver, heart or kidney failure, and those who are allergic to salicylic acid-containing substances. The mechanism of action of the two is different, and their combined use can have a superimposed effect. The combination of clopidogrel and aspirin is generally recommended for acute coronary syndromes, including stent implantation. Specific medications should be prescribed by a physician.